NFKB1 and cancer: Additionally, our in vitro studies showed that the orally available PI3K-inhibitor, PX-866, currently in clinical trials as an anti-cancer agent56 and the potent NF-kB inhibitor, CDDO-Me (Bardoxolone-methyl; BM) currently in clinical trials for chronic kidney disease and diabetes57,58 may be of significant translational value to target the HIV-1 reservoirs.